What Researchers Did
The authors wrote a review that describes hyperbaric oxygen therapy (HBOT), its history and how it is thought to work, and then looks at how it is used in chronic wounds, especially diabetic foot ulcers.
What They Found
This narrative review of hyperbaric oxygen therapy concludes that how HBOT might help chronic wounds is not fully understood and that doubt about its effectiveness remains significant. The abstract reports no trial results, sample sizes or treatment pressures. It says HBOT is considered the mainstay of management for carbon monoxide poisoning, decompression illness and gas embolisms. It also says HBOT has been used for decades as an adjunctive therapy in several medical fields, including chronic wounds, which affect approximately 6.5 million Americans each year. Chronic wounds are described as marked by low oxygen, impaired blood vessel growth and prolonged inflammation, which HBOT may theoretically improve. The authors look closely at the roots of the controversy over diabetic foot ulcers and say that a shortage of high-quality research is a major challenge.
What This Means for Canadian Patients
For people with chronic wounds, including diabetic foot ulcers, this review shows that the benefit of HBOT is still debated and that the quality of the evidence is a major problem. It does not give a recommendation for any one patient. Anyone considering HBOT for a wound should talk with their health care team about the evidence.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This is a descriptive review with no new patient data, and the authors themselves note that the lack of high-quality research makes it hard to judge whether HBOT works for chronic wounds.